Mglur5 (Grm5) Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Neurons expressing metabotropic glutamate receptor 5 (GRM5, also known as mGluR5) represent a critical component of the glutamatergic signaling system in the brain. GRM5 is a Group I metabotropic glutamate receptor that couples to Gq proteins and plays essential roles in synaptic plasticity, learning and memory, and neurological disease pathogenesis. This receptor is a major therapeutic target for neurological and psychiatric disorders. [@grm2020]
Location
GRM5-expressing neurons are widely distributed: [@mglur2022]
Hippocampus: High expression in CA1-CA3 pyramidal neurons, dentate gyrus granule cells
Cortex: Layers II-III and V, pyramidal neurons and interneurons
Striatum: Medium spiny neurons, GABAergic projection neurons
Basal ganglia: Substantia nigra pars reticulata, globus pallidus
Thalamus: Intralaminar nuclei, relay nuclei
Cerebellum: Purkinje cells, deep nuclei
Brainstem: Various nuclei involved in motor control
Mglur5 (Grm5) Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Neurons expressing metabotropic glutamate receptor 5 (GRM5, also known as mGluR5) represent a critical component of the glutamatergic signaling system in the brain. GRM5 is a Group I metabotropic glutamate receptor that couples to Gq proteins and plays essential roles in synaptic plasticity, learning and memory, and neurological disease pathogenesis. This receptor is a major therapeutic target for neurological and psychiatric disorders. [@grm2020]
Location
GRM5-expressing neurons are widely distributed: [@mglur2022]
Hippocampus: High expression in CA1-CA3 pyramidal neurons, dentate gyrus granule cells
Cortex: Layers II-III and V, pyramidal neurons and interneurons
Striatum: Medium spiny neurons, GABAergic projection neurons
Basal ganglia: Substantia nigra pars reticulata, globus pallidus
Thalamus: Intralaminar nuclei, relay nuclei
Cerebellum: Purkinje cells, deep nuclei
Brainstem: Various nuclei involved in motor control
Molecular Characteristics
GRM5 is an 118-kDa class C GPCR: [@metabotropic2021]
Belongs to Group I mGluRs (mGluR1, mGluR5)
Large extracellular venus fly trap domain for glutamate binding
Distinct splice variants (mGluR5a, mGluR5b)
Gq protein coupling activates PLCĪ²
Generates IP3 and DAG second messengers
Releases intracellular calcium from stores
Forms homomers and heteromers with other mGluRs
Interacts with Homer scaffolding proteins
Function
Synaptic Transmission
Regulates NMDA receptor function
Modulates AMPA receptor trafficking
Controls presynaptic release probability
Generates slow excitatory postsynaptic potentials
Synaptic Plasticity
Critical for LTPmechanisms/long-term-potentiation) and LTD induction
Regulates dendritic spine morphology
Controls actin cytoskeleton remodeling
Mediates learning and memory
Calcium Signaling
Mobilizes intracellular calcium stores
Activates calcium-dependent enzymes
Regulates gene transcription
Triggers structural plasticity
Cellular Processes
Neuronal development and migration
Axon guidance
Neuroprotection (under certain conditions)
Pain perception (peripheral and central)
Role in Disease
Alzheimer's Disease (AD)
GRM5 dysfunction contributes to synaptic deficits
Amyloid-beta interacts with mGluR5
Altered expression in AD brains
Target for cognitive enhancement
Parkinson's Disease (PD)
GRM5 in basal ganglia motor circuits
Modulates dopaminergic signaling
Contributes to levodopa-induced dyskinesias
Target for motor complications
Huntington's Disease (HD)
GRM5 hyperactivation contributes to excitotoxicity
Mutant huntingtin alters mGluR5 signaling
Target for neuroprotection
Modulates striatal dysfunction
Fragile X Syndrome (FXS)
GRM5 is a key therapeutic target
Excessive mGluR5 signaling
Negative allosteric modulators in clinical trials
Improves synaptic function
Depression
GRM5 antagonists show antidepressant effects
Rapid-acting mechanisms
Novel treatment target
Modulates stress circuits
Anxiety
Anxiogenic effects of GRM5 activation
Anxiolytic effects of antagonists
Target for anxiety disorders
Pain
mGluR5 in pain transmission
Peripheral and central mechanisms
Target for analgesics
Epilepsy
Pro-convulsant effects of GRM5 activation
Anticonvulsant potential of antagonists
Target for anti-epileptic drugs
Therapeutic Targets
GRM5 is a clinically validated drug target: [@mglur2019]
Negative Allosteric Modulators (NAMs)
Mavoglurant (AFQ056): Clinical trials for Fragile X syndrome
Basimglurant (RO4917523): Depression and anxiety trials
Dipraglurant: Levodopa-induced dyskinesias
Positive Allosteric Modulators (PAMs)
CDPPB: Cognitive enhancement
ADX47273: Investigational for schizophrenia
Applications
Fragile X syndrome: mGluR5 NAMs improve symptoms
Depression: Fast-acting antidepressants
Levodopa-induced dyskinesias: Reduce dyskinesias
Anxiety disorders: Anxiolytic potential
Imaging
11CABP688: PET ligand for mGluR5
Measures receptor availability
Research and clinical applications
Biomarkers
GRM5 serves as a biomarker: [@grm2020a]
Genetic markers: GRM5 polymorphisms in disease
Imaging: PET ligands for receptor density
Expression: Postmortem brain studies
Functional: Treatment response prediction
Background
The study of Mglur5 (Grm5) Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.